Organon & Co. Stock News

Organon & Co. (OGN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon's Interim CEO Joe Morrissey and CFO Matthew Walsh to participate in fireside chat at Piper Sandler Annual Healthcare Conference on December 3.

SHANGHAI & JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon and Henlius announce FDA approval of POHERDY, the first and only pertuzumab biosimilar in the US, which is interchangeable to Perjeta.

Organon & Co. faces ongoing challenges, with shares down over 75% since debut and recent CEO resignation after inventory probe. OGN Q3 results show stagnant revenues, declining Women's Health sales, and persistent high debt, despite low valuation metrics like a 3.7x forward P/E. Dividend has been slashed, Nexplanon sales fell 50% in the US in Q3, and the company is selling assets to manage leve...

Organon & Co. ( OGN ) Q3 2025 Earnings Call November 10, 2025 8:30 AM EST Company Participants Jennifer Halchak - Head of Investor Relations Carrie Cox Joseph Morrissey - Interim CEO & Executive VP and Head of Manufacturing & Supply Matthew Walsh - Executive VP & CFO Conference Call Participants Jason Gerberry - BofA Securities, Research Division David Amsellem - Piper Sandler & Co., Research D...

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN) today announced its results for the third quarter ended September 30, 2025. “I am humbled to be working alongside our talented team during this pivotal time for Organon,” said Joe Morrissey, Organon's Interim Chief Executive Officer. “We are harnessing the company's many strengths, including a diverse portfolio that we expect will generate...

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon divests the JADA System for up to $465 Million to Laborie.

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon to announce Q3 2025 financial results on November 10, 2025.